Somatostatin Receptor Positive Neuroendocrine Tumours (NETs)
Conditions
Brief summary
Presence of participants with second primary haematological and non-haematological malignancies
Detailed description
Incidence of treatment-related adverse events of any grade according to the National Cancer Institute–Common Terminology Criteria for Adverse Events Version 5.0, including any treatment-related serious adverse events, as assessed by the investigators, Changes over time in laboratory tests (haematology and biochemistry), Overall survival defined as the time from the first dose of 177Lu-IPN01072 until death from any cause
Interventions
None listed
Sponsors
Ariceum Therapeutics GmbH
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Presence of participants with second primary haematological and non-haematological malignancies | — |
Secondary
| Measure | Time frame |
|---|---|
| Incidence of treatment-related adverse events of any grade according to the National Cancer Institute–Common Terminology Criteria for Adverse Events Version 5.0, including any treatment-related serious adverse events, as assessed by the investigators, Changes over time in laboratory tests (haematology and biochemistry), Overall survival defined as the time from the first dose of 177Lu-IPN01072 until death from any cause | — |
Countries
France
Outcome results
None listed